Mutation patterns of the reverse transcriptase and protease genes in humanimmunodeficiency virus type 1-infected patients undergoing combination therapy: Survey of 787 sequences
N. Yahi et al., Mutation patterns of the reverse transcriptase and protease genes in humanimmunodeficiency virus type 1-infected patients undergoing combination therapy: Survey of 787 sequences, J CLIN MICR, 37(12), 1999, pp. 4099-4106
The aim of the present study was to evaluate the resistance-associated muta
tions in 302 human immunodeficiency virus type 1 (HIV-l)-infected patients
receiving combination therapy and monitored in Marseille, France, hospitals
from January 1997 to June 1998, In the reverse transcriptase (RT) gene, th
e most frequent mutations were found at codons 215 (53%), 41 (34%), and 67,
70, 184, and 210 (>20%), One deletion and two insertions in the beta 3-bet
a 4 hairpin loop of the finger subdomain (codon 69) were detected. Interest
ing associations and/or exclusions of specific mutations were observed, In
96% of RT genes, a mutation at codon 70 (most frequently, K70R) was associa
ted with a wild-type genotype at position 210 (P < 10(-5)). Similarly, a mu
tation at codon 210 (most frequently, L210W) was generally associated with
mutations at codons 41 (92%) and 215 (96%) but not at codon 219 (16%) or co
don 70 (4%) (P < 10(-5)). In the protease gene, the most prevalent mutation
s were at codons 63 (84%), followed by codons 10, 36, 71, 77, and 93 (ca. 2
0%), As for RT, pairwise associations of mutations were observed. Analysis
of the mutation patterns for patients with undetectable HIV-1 loads reveale
d a high proportion (65%) of wild-type RT genotypes but only 18% wild-type
protease genotypes, For patients with high viral loads (>100,000 copies/ml)
, more than 50% of the RT and protease genes displayed three or more mutati
ons. The significant correlation between the level of viremia in plasma and
the number of resistance mutations in the protease (P = 0.007) and RT (P =
0.00078) genes strengthens the importance of defining the genotype of the
predominant HIV-I quasispecies before initiating antiretroviral therapy.